Actively Recruiting
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Led by Navy General Hospital, Beijing · Updated on 2024-10-29
52
Participants Needed
1
Research Sites
308 weeks
Total Duration
On this page
Sponsors
N
Navy General Hospital, Beijing
Lead Sponsor
C
Chinese PLA General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed/refractory peripheral t-cell lymphomas.
CONDITIONS
Official Title
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed angioimmunoblastic T-cell lymphoma according to WHO classification
- 18 years of age or older at the time of signing informed consent
- Ability to understand and voluntarily sign informed consent form
- Willingness and ability to follow study visit schedule and protocol requirements
- Relapsed or refractory angioimmunoblastic T-cell lymphoma after at least one systemic therapy
- Meeting specific lab criteria: Absolute Neutrophil Count ≥ 1.5 x 10^9/L (≥ 1 x 10^9/L if bone marrow involvement), Platelets ≥ 75 x 10^9/L (≥ 50 x 10^9/L if bone marrow involvement), Hemoglobin ≥ 8 g/dL
- Anticipated life expectancy of at least 3 months
You will not qualify if you...
- Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment
- Unstable systemic diseases needing therapy, including severe heart, liver, kidney, or metabolic diseases
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Navy General Hospital
Beijing, Beijing Municipality, China, 100048
Actively Recruiting
Research Team
L
Liren Qian, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here